Cepheid (Nasdaq: CPHD) reported earnings on Jan. 26. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Cepheid beat expectations on revenue and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue improved significantly, and GAAP earnings per share increased.

Margins contracted across the board.

Revenue details
Cepheid recorded revenue of $80.1 million. The 19 analysts polled by S&P Capital IQ expected net sales of $73.8 million. Sales were 36% higher than the prior-year quarter's $58.7 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions.

EPS details
Non-GAAP EPS came in at -$0.03. The 12 earnings estimates compiled by S&P Capital IQ predicted $0.00 per share on the same basis. GAAP EPS of $0.03 for Q4 were 263% lower than the prior-year quarter's $0.02 per share.

Source: S&P Capital IQ. Quarterly periods. Figures may be non-GAAP to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 51.8%, 300 basis points worse than the prior-year quarter. Operating margin was -1.7%, 480 basis points worse than the prior-year quarter. Net margin was -2.1%, 440 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $76.8 million. On the bottom line, the average EPS estimate is -$0.02.

Next year's average estimate for revenue is $340.6 million. The average EPS estimate is $0.26.

Investor sentiment
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 237 members out of 262 rating the stock outperform, and 25 members rating it underperform. Among 77 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 73 give Cepheid a green thumbs-up, and four give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cepheid is outperform, with an average price target of $41.23.

The biotechnology and healthcare investing landscape is littered with also-rans and a few major winners. Is Cepheid the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.